Description

Simple

Clinical

Overview

Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a sedative. Side effects include dizziness and headaches.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Mebutamate
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Mebutamate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Mebutamate.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Mebutamate.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Mebutamate is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Mebutamate.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Mebutamate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Mebutamate.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Mebutamate.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Mebutamate.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Mebutamate.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Mebutamate is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Mebutamate.
Adipiplon
The risk or severity of adverse effects can be increased when Adipiplon is combined with Mebutamate.
Agomelatine
The risk or severity of adverse effects can be increased when Agomelatine is combined with Mebutamate.
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Mebutamate.
Alaproclate
The risk or severity of adverse effects can be increased when Mebutamate is combined with Alaproclate.
Alcuronium
The risk or severity of adverse effects can be increased when Mebutamate is combined with Alcuronium.
Alfaxalone
The risk or severity of adverse effects can be increased when Mebutamate is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Mebutamate.
1 References
  1. 1 . Tetreault L, Richer P, Bordeleau JM: Hypnotic properties of mebutamate: a comparative study of mebutamate, secobarbital and placebo in psychiatric patients. Can Med Assoc J. 1967 Aug 19;97(8):395-8.PubMed: 6037393